JOHN PULLMAN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- BUTTE, MT
- NPI
- 1518998426
- Received
- $34,791 in 470 records, 2019 to 2025 ($18,717 general, $16,074 research)
- As principal investigator
- $5,943,987 of research payments to others in 1,320 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 61 | $2,134 |
| 2024 | General payment | 85 | $5,921 |
| 2024 | Research payment | 23 | $3,263 |
| 2023 | General payment | 76 | $2,969 |
| 2023 | Research payment | 1 | $690 |
| 2022 | General payment | 61 | $3,274 |
| 2021 | General payment | 51 | $764 |
| 2020 | General payment | 38 | $573 |
| 2020 | Research payment | 2 | $12,120 |
| 2019 | General payment | 72 | $3,079 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 26 | $16,074 |
| Travel and Lodging | 37 | $9,717 |
| Food and Beverage | 404 | $8,389 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $562 |
| Education | 2 | $47 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Corcept Therapeutics | $19 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-15 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-12-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $23 | Food and Beverage | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2025 | |
| 2025-12-03 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-11-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-11-20 | Novo Nordisk Inc | $5 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-19 | ABBVIE INC. | $46 | Food and Beverage | In-kind items and services | EMBLAVEO Drug, ANTI-INFECTIVE | 2025 | |
| 2025-10-15 | ABIOMED | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-14 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-30 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-09-30 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-09-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-09-24 | Bayer Healthcare Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-Renal | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-09-11 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-09-04 | Inspire Medical Systems, Inc. | $20 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-08-25 | Lilly USA, LLC | $9 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-08-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-08-12 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-07-18 | Medtronic, Inc. | $18 | Food and Beverage | In-kind items and services | INCEPTIV Device, Spinal Cord Neurostimulation | 2025 | |
| 2025-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-17 | Lilly USA, LLC | $3 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-07-16 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-14 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-06-26 | Boston Scientific Corporation | $38 | Food and Beverage | In-kind items and services | WATCHMAN FLX Device, WATCHMAN FLX_IC | 2025 | |
| 2025-06-19 | Exact Sciences Corporation | $23 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2025 | |
| 2025-06-18 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-06-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-06-12 | Medtronic, Inc. | $28 | Food and Beverage | In-kind items and services | MINIMED 780G Device, Durable Pump | 2025 | |
| 2025-06-11 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-06-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-06-02 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-05-21 | GlaxoSmithKline, LLC. | $17 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-05-15 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-05-14 | Insulet Corporation | $49 | Food and Beverage | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2025 | |
| 2025-05-13 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-05 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-04-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $36 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-04-23 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2025 | |
| 2025-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $250 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $129 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $80 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $78 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $49 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $38 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | $38 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-24 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-03-24 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-20 | Corcept Therapeutics | $13 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-03-11 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-03-10 | Amgen Inc. | $7 | Food and Beverage | In-kind items and services | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2025 | |
| 2025-02-13 | Exact Sciences Corporation | $27 | Food and Beverage | In-kind items and services | Cologuard Collection Kit Device, Oncology | 2025 | |
| 2025-02-12 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2025 | |
| 2025-02-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $203 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $198 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-02-07 | Novo Nordisk Inc | $6 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-01-28 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-01-22 | AstraZeneca Pharmaceuticals LP | $135 | Food and Beverage (17 payments) | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2024-12-18 | Lundbeck LLC | $18 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-12-03 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-11-07 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-11-04 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-11-03 | Zealand Pharma A/S | $1,195 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-11-03 | Zealand Pharma A/S | $150 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-30 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-10-30 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-10-09 | Lundbeck LLC | $15 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-10-02 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | TEFLARO Drug, ANTI-INFECTIVE | 2024 | |
| 2024-09-30 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-09-26 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-09-24 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-09-24 | Novo Nordisk Inc | $2 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-09-23 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-09-19 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-11 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-09-11 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-09-10 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-08-28 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-08-27 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-08-18 | Eli Lilly and Company | $745 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-08-13 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-08-06 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-08-06 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-07-26 | Regeneron Pharmaceuticals, Inc. | $305 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-26 | Regeneron Pharmaceuticals, Inc. | $233 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-26 | Regeneron Pharmaceuticals, Inc. | $70 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-26 | Regeneron Pharmaceuticals, Inc. | $60 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-26 | Regeneron Pharmaceuticals, Inc. | $44 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-26 | Regeneron Pharmaceuticals, Inc. | $15 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-26 | Regeneron Pharmaceuticals, Inc. | $15 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-25 | Regeneron Pharmaceuticals, Inc. | $128 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-25 | Regeneron Pharmaceuticals, Inc. | $32 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-23 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-07-23 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2024 | |
| 2024-07-17 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-07-16 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-07-16 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-07-11 | Regeneron Pharmaceuticals, Inc. | $565 | Research payment | In-kind items and services | A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to S | 2024 | |
| 2024-07-11 | Novo Nordisk Inc | $20 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-10 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-07-08 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-06-26 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-06-25 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2024 | |
| 2024-06-17 | Eli Lilly and Company | $339 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $320 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $320 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $237 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $103 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $102 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $65 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $65 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $42 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $32 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $28 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $28 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $15 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-17 | Eli Lilly and Company | $15 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $622 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $357 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-16 | Eli Lilly and Company | $76 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-06-12 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-05-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-05-28 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-05-23 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | JARDIANCE Drug, Diabetes | 2024 | |
| 2024-05-20 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-05-16 | Lilly USA, LLC | $7 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-05-15 | Novo Nordisk Inc | $10 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-09 | Novo Nordisk Inc | $6 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2024 | |
| 2024-05-02 | PFIZER INC. | $11 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2024 | |
| 2024-04-25 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-04-18 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-04-12 | ABBVIE INC. | $760 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-12 | ABBVIE INC. | $69 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-12 | ABBVIE INC. | $50 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-12 | ABBVIE INC. | $37 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-11 | ABBVIE INC. | $226 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-11 | ABBVIE INC. | $125 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-11 | ABBVIE INC. | $70 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-11 | ABBVIE INC. | $50 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-11 | ABBVIE INC. | $37 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-11 | ABBVIE INC. | $25 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-10 | ABBVIE INC. | $226 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 |
| 2024-04-10 | ABBVIE INC. | $67 | Research payment | In-kind items and services | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 | |
| 2024-04-10 | ABBVIE INC. | $45 | Research payment | In-kind items and services | A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Sa | 2024 | |
| 2024-03-27 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-03-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-03-21 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-12 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-03-12 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-02-26 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-02-20 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2024 | |
| 2024-02-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-02-08 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2024 | |
| 2024-02-08 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | DALVANCE Drug, ANTI-INFECTIVE | 2024 | |
| 2024-02-07 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-02-06 | AstraZeneca Pharmaceuticals LP | $138 | Food and Beverage (18 payments) | In-kind items and services | AIRSUPRA Drug, Respiratory | 2024 | |
| 2024-01-25 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-01-25 | Novo Nordisk Inc | $7 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-23 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2024 | |
| 2024-01-22 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-01-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2024 | |
| 2024-01-16 | Lilly USA, LLC | $9 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2024 | |
| 2024-01-10 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-01-03 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2023-12-20 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-12-18 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-12-11 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-12-06 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-11-29 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2023 | |
| 2023-11-20 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2023 | |
| 2023-11-16 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-12 | Novo Nordisk AS | $690 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN SELECT Results Meeting Philadelphia | 2023 |
| 2023-11-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2023 | |
| 2023-10-31 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-10-25 | Boehringer Ingelheim International GmbH | $351 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $145 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $145 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $65 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $50 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $50 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $25 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $25 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $25 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-25 | Boehringer Ingelheim International GmbH | $25 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-16 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-10-04 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-10-03 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | Otezla Drug, Inflammation | 2023 | |
| 2023-09-27 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-09-06 | Boehringer Ingelheim International GmbH | $453 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-08-30 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-08-24 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | ENTRESTO Drug, Cardiology/Vascular Diseases | 2023 | |
| 2023-08-23 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-23 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2023 | |
| 2023-08-22 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2023 | |
| 2023-08-15 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2023 |
The latest 200 records of 470.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | MERCURY STREET MEDICAL GROUP PLLC | $5,520 | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and sa | 2025 |
| 2025-12-19 | Hoffmann-La Roche Limited | MERCURY STREET MEDICAL GROUP PLLC | $4,754 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $6 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $146 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | MERCURY STREET MEDICAL | $3,629 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-05 | ABBVIE INC. | MERCURY STREET MEDICAL GROUP PLLC | $1,146 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-12-04 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $7,902 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-20 | Hoffmann-La Roche Limited | MERCURY STREET MEDICAL GROUP PLLC | $10,154 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-11-14 | Hoffmann-La Roche Limited | MERCURY STREET MEDICAL GROUP PLLC | $19,320 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-11-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | MERCURY STREET MEDICAL | $19,107 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | MERCURY STREET MEDICAL | $269 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-05 | Novo Nordisk AS | MERCURY STREET MEDICAL GROUP, PLLC | $1,000 | NN9535-4801 | 2025 |
| 2025-11-05 | Novo Nordisk AS | MERCURY STREET MEDICAL GROUP, PLLC | $500 | NN9535-4801 | 2025 |
| 2025-11-05 | ABBVIE INC. | MERCURY STREET MEDICAL GROUP PLLC | $14,320 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $139 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | MERCURY STREET MEDICAL GROUP, PLLC | $24,272 | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $19 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $73 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-16 | Hoffmann-La Roche Limited | MERCURY STREET MEDICAL GROUP PLLC | $14,798 | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity | 2025 |
| 2025-10-16 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $5,600 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-10-09 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $1,926 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $10 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $219 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-18 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $5,268 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-09-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | MERCURY STREET MEDICAL | $840 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $30 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $146 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $81 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $18 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-26 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $1,838 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $3,500 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-08-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | MERCURY STREET MEDICAL | $14,510 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $1 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-28 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $36 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-22 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $1,316 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-07-21 | Novo Nordisk AS | MERCURY STREET MEDICAL GROUP, PLLC | $5,036 | NN9535-4801 | 2025 |
| 2025-07-04 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $2,184 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-07-02 | ABBVIE INC. | MERCURY STREET MEDICAL GROUP PLLC | $3,923 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-07-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | MERCURY STREET MEDICAL | $13,372 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $182 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-24 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $434 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $8 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-24 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $18 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-12 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $8,128 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-06-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | MERCURY STREET MEDICAL | $2,930 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-03 | ABBVIE INC. | MERCURY STREET MEDICAL GROUP PLLC | $14,859 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-06-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $26,938 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $1,487 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $7,422 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $7,000 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-05-28 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $2,041 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-05-27 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $6 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-05-27 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $219 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-05-23 | Regeneron Pharmaceuticals, Inc. | MERCURY STREET MEDICAL GROUP PLLC | $75,347 | A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO S | 2025 |
| 2025-05-07 | ABBVIE INC. | MERCURY STREET MEDICAL GROUP PLLC | $3,439 | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H | 2025 |
| 2025-05-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $39 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-05-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $49 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
| 2025-05-01 | Boehringer Ingelheim International GmbH | MERCURY STREET MEDICAL | $47 | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Butte-Silver Bow, MT, county Silver Bow County, MT, state Montana; placed by its city name.
| Measure | Place (city or town) Butte-Silver Bow, MT | County Silver Bow County, MT | State Montana |
|---|---|---|---|
| Population B01003 | 35,052 | 35,785 | 1,116,875 |
| Population, 2020 census P1 | 34,494 | 35,133 | 1,084,225 |
| Median age B01002 | 40.6 | 40.5 | 40.4 |
| Under 18 B01001 | 20.2% | 20.2% | 21.0% |
| 65 and over B01001 | 19.5% | 19.5% | 20.1% |
| Households B11001 | 15,127 | 15,419 | 458,859 |
| Foreign born B05002 | 1.2% | 1.2% | 2.3% |
| Median household income B19013 | $61,857 | $61,754 | $72,509 |
| Median family income B19113 | $82,625 | $82,641 | $92,794 |
| Per capita income B19301 | $36,035 | $35,951 | $41,711 |
| Poverty rate B17001 | 14.8% | 14.8% | 11.5% |
| Unemployment rate B23025 | 4.0% | 4.1% | 3.6% |
| Civilian labor force B23025 | 17,262 | 17,630 | 568,568 |
| Mean commute (minutes) B08013 | 16.9 | 16.9 | 19.1 |
| Bachelor's degree or higher B15003 | 28.1% | 28.0% | 35.2% |
| Housing units B25001 | 17,158 | 17,499 | 528,419 |
| Owner-occupied B25003 | 70.7% | 70.8% | 69.2% |
| Renters B25003 | 29.3% | 29.2% | 30.8% |
| Median home value B25077 | $257,800 | $255,200 | $375,800 |
| Median gross rent B25064 | $856 | $863 | $1,081 |
| White, not Hispanic B03002 | 89.0% | 89.1% | 83.6% |
| Black B03002 | 0.1% | 0.1% | 0.4% |
| Hispanic or Latino B03002 | 4.7% | 4.6% | 4.6% |
| Asian B03002 | 0.4% | 0.4% | 0.8% |
| American Indian and Alaska Native B03002 | 1.4% | 1.4% | 5.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Butte-Silver Bow, MT.
Comments